Zenas BioPharma
A global biopharma company developing and commercializing immune-based therapies.
The USA-based company's lead product, obexelimab (ZB012), is a Phase III, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Zenas acquired exclusive worldwide rights to obexelimab from Xencor.
In November 2022, the company announced proceeds of $118 million in connection with the issuance of Series B preferred shares.
Latest Zenas BioPharma News & Features
1 July 2024
4 December 2023
8 December 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze